The relationship between fibroblast growth factor receptor type 2 and clinical characteristics of primary/recurrent ameloblastoma

doi:10.19438/j.cjoms.2017.03.013

Abstract

Abstract: PURPOSE: To detect the immunohistochemical expression of fibroblast growth factor receptor type 2 (FGFR2) in primary ameloblastoma and recurrent ameloblastoma, and to determine its role in development of ameloblastoma, especially in invasion and recurrence of ameloblastoma. METHODS: Ninety-six formalin-fixed, paraffin-embedded tissue blocks of ameloblastoma specimens from 32 patients who had two surgeries due to recurrence and 32 patients who had only one surgery were compared at protein expression level using immunohistochemistry for FGFR2 staining. Statistical analysis was performed by use of SAS 9.3 software package, to determine the relationship between the expression of FGFR2 and clinical parameters. RESULTS: FGFR2 immunostaining was evident in all specimens, the staining in recurrent ameloblastoma was significantly stronger than in primary ameloblastoma. Statistical analysis showed that FGFR2 expression was significantly higher in recurrent ameloblastoma than in primary ameloblastoma; FGFR2 expression was significantly higher in maxillary recurrent ameloblastoma than in mandibular recurrent ameloblastoma; patient with tumor size over 3.9 cm had a higher rate of recurrence. CONCLUSION: High expression of FGFR2 plays an important role in invasion and recurrence of ameloblastoma.

Key words: Jaw bone, Recurrent ameloblastoma, Primary ameloblastoma, FGFR2

CLC Number:

R739.8

TANG Yu, JI Tong.. The relationship between fibroblast growth factor receptor type 2 and clinical characteristics of primary/recurrent ameloblastoma[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(3): 254-258.

References

[1] Almeida Rde A, Andrade ES, Barbalho JC, et al. Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis [J]. Int J Oral Maxillofac Surg, 2016, 45(3): 359-367.
[2] Rastogi V, Pandilwar PK, Maitra S. Ameloblastoma: an evidence based study [J]. J Maxillofac Oral Surg, 2010, 9(2): 173-177.
[3] Nakamura N, Higuchi Y, Mitsuyasu T, et al. Comparison of long-term results between different approaches to ameloblastoma [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002, 93(1): 13-20.
[4] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy [J]. Nat Rev Drug Discov, 2009, 8(3): 235-253.
[5] Wilkie AO, Morriss-Kay GM, Jones EY, et al. Functions of fibroblast growth factors and their receptors [J]. Curr Biol,1995, 5(5):500-507.
[6] Cormier S, Leroy C, Delezoide AL, et al. Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development [J]. Gene Expr Patterns, 2005, 5(4): 569-573.
[7] Li X, Wang C, Xiao J, et al. Fibroblast growth factors, old kids on the new block [J]. Semin Cell Dev Biol, 2016, 53: 155-167.
[8] Kettunen P, Laurikkal J, It ranta P, et al. Association of FGF-3 and FGF-10 with signaling networks regulating tooth morphogenesis [J]. Dev Dyn, 2000, 219(3): 322-332
[9] Klein OD, Lyons DB, Balooch G, et al. An FGF signaling loop sustains the generation of differentiated progeny from stem cells in mouse incisors [J]. Development, 2008, 135(2): 377-385.
[10] Han N, Kim MA, Lee HS, et al. Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer [J]. Pathobiology, 2015, 82(6): 269-279.
[11] Liu K, Song X, Zhu M, et al. Overexpression of contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts [J]. Oncol Lett, 2015, 10(4): 2003-2008.
[12] Mathur A, Ware C, Davis L, et al. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival [J]. PLoS One, 2014, 9(6): e98515.
[13] Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer [J]. PLoS Biol, 2008, 6(5): e108.
[14] Nomura S, Yoshitomi H, Takano S, et al. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer [J]. Br J Cancer, 2008, 99(2): 305-313.
[15] 李琳琳, 刘云鹏, 侯柯佐, 等. FGFR2和c-Cbl在胃癌组织中的表达及其临床意义 [J]. 中国癌症杂志, 2009, 19(8): 609-614.
[16] 覃山羽, 姜海行, 李信, 等. 胃癌及癌前病变中bFGF 、 FGFR-2及Hpa的表达及其意义[J]. 中国实用内科杂志, 2007, 27(17): 1379-1383.
[17] 郑永华, 牟一平, 张锐利, 等. 成纤维细胞生长因子2（FGFR2）在直肠癌中的表达意义[D]. 杭州: 浙江大学, 2011.
[18] Sato T, Oshima T, Yoshihara K, et al. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer[J]. Oncol Rep, 2009, 21(1): 211-216.
[19] Brown NA, Rolland D, McHugh JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma [J]. Clin Cancer Res, 2014, 20(21): 5517-5526.
[20] Diniz MG, Gomes CC, Guimar es BV, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours [J]. Tumour Biol, 2015,36(7): 5649-5653.
[21] Nakao Y, Mitsuyasu T, Kawano S, et al. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway [J]. Int J Oncol, 2013, 43(5): 1377-1384.
[22] Martin AJ, Grant A, Ashfield AM, et al. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype [J]. BMC Res Notes, 2011, 4: 72.
[23] Mcinerney N, Colleran G, Rowan A, et al. Low penetrance breast cancer predisposition SNPs are site specific [J]. Breast Cancer Res Treat, 2009, 117(1): 151-159.